Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-powered evaluation of dementia severity based on clinical data and visual scoring systems (MTA, ERICA, GCA) from MRI.

Scientific reports·2026
Same author

Cost-utility analysis of cerebrospinal fluid versus blood biomarkers for early detection of Alzheimer's disease and mild cognitive impairment in Thailand: a modeling study.

BMC health services research·2026
Same author

Web-Based Application for Cognitive and Functional Assessments in Dementia Screening: Mixed Methods, User-Centered Development Approach.

JMIR human factors·2026
Same author

Psychometric validation and cross-cultural adaptation of the dementia knowledge assessment Scale-Thai (DKAS-Thai).

BMC geriatrics·2026
Same author

Dementia Care Research and Psychosocial Factors.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Vorapun Senanarong1,2, Tanyaluck Thientunyakit3, Chatchawan Rattanabannakit2

  • 1Division of Neurology, Department of Medicine, Faculty of Medicine, Siriraj hospital, Mahidol university, Bangkok, Thailand.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary
This summary is machine-generated.

This study identified optimal cut-off values for plasma biomarkers to diagnose Alzheimer's disease (AD) in Thailand. Plasma p-tau217 demonstrated the highest accuracy in distinguishing AD from non-AD groups.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Area of Science:

  • Neurology
  • Biomarker Discovery
  • Dementia Diagnostics

Background:

  • Alzheimer's disease (AD) diagnosis relies on invasive methods.
  • Plasma-based biomarkers offer a less invasive alternative for AD detection.
  • Establishing local cut-off values is crucial for population-specific accuracy.

Purpose of the Study:

  • To determine local cut-off values for plasma biomarkers in Alzheimer's disease (AD).
  • To assess the diagnostic performance of plasma biomarkers in differentiating AD from non-AD subgroups within the Thai population.
  • To validate plasma biomarkers against amyloid PET and CSF markers.

Main Methods:

  • Prospective study involving 97 participants (AD, non-AD dementia, MCI/controls).
  • Aβ-PET (18F-florbetapir) and plasma biomarkers (Aβ40, Aβ42, p-tau181, pTau217, GFAP) were analyzed.
  • Receiver Operating Characteristic (ROC) analysis was used to determine cut-off values.

Main Results:

  • Plasma p-tau217 showed the highest accuracy (87.14%) in differentiating AD positive from AD negative groups.
  • Plasma GFAP (77.89%), pTau181 (73.20%), and Aβ42/40 ratio (72.63%) also demonstrated significant diagnostic performance.
  • All tested plasma biomarkers showed promising diagnostic capabilities.

Conclusions:

  • Plasma biomarkers exhibit significant potential for clinical use in dementia diagnosis.
  • Plasma p-tau217 is the most effective biomarker for discriminating AD.
  • These findings support the use of plasma biomarkers for AD diagnosis in the Thai population.